Company intelligence / Profile preview
Terran Biosciences
New York, New York, United Statesterranbiosciences.com ↗
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
Terran Biosciences is advancing several late-stage assets, including therapies for schizophrenia and depression. They have developed novel forms of MDMA and psilocybin, aiming for rapid FDA approval via the 505(b)(2) pathway.
- Therapeutic areas
- PsychiatryNeurology
- Modalities
- Small moleculesPsychedelic therapiesAI-enabled imaging software
- Industry
- Biotech
02
Drug pipeline
10 assets9 more assets in the full pipeline.
03
Partnerships
Sanofi (licensing deal for CNS pipeline assets)
Beyond the preview
Go deeper on Terran Biosciences.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Terran Biosciences.